Multiple tumour-agnostic kinase inhibitors have been approved that are clinically effective regardless of tumour location. This Review describes the origins of tumour-agnostic drug development, focusing on small-molecule inhibitors that target kinase pathway aberrations, and discusses the challenges in developing tissue-agnostic agents.